Cargando…

Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia

Australia introduced the 7-valent pneumococcal conjugate vaccine (7vPCV) on the universal infant National Immunisation Program (NIP) in 2005 and replaced it with the 13-valent pneumococcal conjugate vaccine (13vPCV) in 2011, both under a 3 + 0 schedule. The objective of this analysis was to quantify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perdrizet, Johnna, Lai, Yuen S., Williams, Scott, Struwig, Valda A., Wasserman, Matt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954941/ https://www.ncbi.nlm.nih.gov/pubmed/33575966 http://dx.doi.org/10.1007/s40121-021-00409-7

Ejemplares similares

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium
por: Wilson, Michele R., et al.
Publicado: (2021)

Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States
por: Perdrizet, Johnna, et al.
Publicado: (2023)

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age
por: Wasserman, Matt D., et al.
Publicado: (2021)

Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
por: Wilson, Michele, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease
por: Huang, Liping, et al.
Publicado: (2023)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
por: Warren, Sophie, et al.
Publicado: (2023)

A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
por: Li, Xiuyan, et al.
Publicado: (2023)

576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022)

Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt
por: Sevilla, JP, et al.
Publicado: (2022)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
por: Wilson, Michele, et al.
Publicado: (2023)

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
por: Shen, Kunling, et al.
Publicado: (2018)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
por: Pugh, Sarah J., et al.
Publicado: (2018)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023)

1384. Conceptual Economic Model Methodology for Infant Pneumococcal Conjugate Vaccine Program and its Impact on Antimicrobial Resistance
por: Farkouh, Raymond, et al.
Publicado: (2020)

Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
por: Sings, Heather L., et al.
Publicado: (2021)

Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK
por: Wasserman, M., et al.
Publicado: (2018)

Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
por: Wilson, Michele, et al.
Publicado: (2018)

Effectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine
por: Antony, Katja, et al.
Publicado: (2005)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
por: Mackenzie, Grant A., et al.
Publicado: (2022)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants
por: Rückinger, Simon, et al.
Publicado: (2010)

2701. The Impact of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Children in British Columbia, Canada
por: Vadlamudi, Nirma K, et al.
Publicado: (2019)

2706. Indirect Effects of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Adults in British Columbia, Canada
por: Vadlamudi, Nirma K, et al.
Publicado: (2019)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
por: Breton, Marie-Claude, et al.
Publicado: (2018)

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
por: Pugh, Sarah, et al.
Publicado: (2020)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants
por: Lin, Nancy D, et al.
Publicado: (2005)

Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2017)

Indirect Effects of Pneumococcal Conjugate Vaccines in National Immunization Programs for Children on Adult Pneumococcal Disease
por: Kim, Young Keun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jid8seporm49v0p0kt9sps57a3